Michelle Nguyen

Michelle Nguyen supports the procurement mission of the National Cancer Institute (NCI) by managing complex acquisitions aligned with the agency’s strategic focus on advancing cancer research through innovative scientific infrastructure and technical services. She oversees the acquisition of mission-critical resources that enable high-throughput genomic analysis, data-driven diagnostics, and precision medicine platforms, ensuring alignment with NIH’s translational research goals. Her portfolio typically includes contracts for research support services, data infrastructure, and specialized laboratory equipment, often requiring compliance with federal biomedical procurement regulations and interagency collaboration protocols. Her primary contractor relationships center on Roche Diagnostics Corporation, reflecting a consistent reliance on industry leaders in molecular diagnostics and cancer research technologies. She engages with vendors capable of delivering integrated diagnostic systems, bioinformatics platforms, and clinical-grade analytical tools, often requiring rigorous validation and regulatory compliance. Her contracting patterns indicate a preference for established, high-capability providers with proven expertise in translational oncology and laboratory-developed test frameworks, suggesting a focus on mission-critical, low-risk procurement strategies. Michelle’s procurement activity shows no use of socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a prioritization of technical capability and scientific readiness over socioeconomic preferences, consistent with NCI’s emphasis on accelerating high-stakes research timelines. While small business participation is not formally incentivized, her acquisitions remain open to all qualified vendors meeting stringent technical and operational requirements. Her NAICS focus areas reveal a strong alignment with computing infrastructure providers, software publishers, and professional management consulting services—indicating expertise in procuring cloud-based data platforms, bioinformatics software, and research operations support. She also engages in real estate leasing for specialized research facilities, underscoring her role in enabling the physical and digital ecosystems required for cutting-edge cancer research.